Stockscreener 앱 받기
38.38
0.39%
-0.15
시간 외 거래:
38.46
0.08
+0.21%
Royalty Pharma Plc 주식(RPRX)의 최신 뉴스
Royalty Pharma shares edge higher on acquisition of oncology drug royalties - MSN
Nuvalent’s Royalty Interest Acquired by Royalty Pharma - TipRanks
Royalty Pharma stock rises after acquiring cancer drug royalties By Investing.com - Investing.com Australia
Royalty Pharma stock rises after acquiring cancer drug royalties - Investing.com India
Royalty Pharma Acquires Royalty Interest in Nuvalent's Potential Lung Cancer Therapies - marketscreener.com
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million - The Manila Times
Royalty Pharma acquires royalty interest in cancer drugs for $315 million - Investing.com
Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million - Quiver Quantitative
Royalty Pharma acquires drug royalty rights for up to $315 million - StreetInsider
Royalty Pharma (Nasdaq: RPRX) buys Nuvalent NSCLC royalties for up to $315M - Stock Titan
Squarepoint Ops LLC Makes New $9.85 Million Investment in Royalty Pharma PLC $RPRX - MarketBeat
Eventide Asset Management LLC Buys 41,830 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Adage Capital Partners GP L.L.C. Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Main Street Financial Solutions LLC Buys 31,844 Shares of Royalty Pharma PLC $RPRX - MarketBeat
TD Cowen Maintains Royalty Pharma (RPRX) Buy Recommendation - Nasdaq
TD Cowen raises Royalty Pharma stock price target on growth outlook By Investing.com - Investing.com South Africa
Precision Trading with Royalty Pharma Plc (RPRX) Risk Zones - news.stocktradersdaily.com
TD Cowen Forecasts Strong Price Appreciation for Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
RPRX: TD Cowen Raises Price Target for Royalty Pharma | RPRX Sto - GuruFocus
TD Cowen raises Royalty Pharma stock price target on growth outlook - Investing.com Nigeria
Royalty Pharma (RPRX) PT Raised at TD Cowen; 'Best Ideas 2026: Unique Business' - StreetInsider
First Trust Advisors LP Has $39.78 Million Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
California Public Employees Retirement System Sells 268,263 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) EVP Sells $913,526.10 in Stock - MarketBeat
Hsbc Holdings PLC Sells 77,498 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Holdings Raised by Amundi - MarketBeat
Denali enters into a $275M funding deal with Royalty Pharma - MSN
What Royalty Pharma (RPRX)'s Denali Rare-Disease Royalty Deal and Cash Surge Means For Shareholders - Sahm
Royalty Pharma (NASDAQ:RPRX) EVP Sells $4,374,700.00 in Stock - MarketBeat
11% Of This Royalty Pharma Insider's Holdings Were Sold - 富途牛牛
Royalty Pharma Insider Sold Shares Worth $4,375,008, According to a Recent SEC Filing - marketscreener.com
What's Going On With Denali Therapeutics Stock Friday?Denali Therapeutics (NASDAQ:DNLI) - Benzinga
Royalty Pharma (RPRX): Assessing Valuation After a Strong Multi‑Month Share Price Rally - Sahm
Denali Enters Into a $275M Funding Deal With Royalty Pharma - Prime Publishers, Inc.
Is It Too Late to Reassess Royalty Pharma After Its 52% Surge in 2025? - Yahoo Finance
Royalty Pharma PLC $RPRX Shares Acquired by Schroder Investment Management Group - MarketBeat
Denali makes $275m funding agreement with Royalty Pharma - Yahoo Finance
Will Royalty Pharma plc (RPD) stock maintain strong growth2025 Valuation Update & Reliable Volume Spike Trade Alerts - Newser
Royalty Pharma (NASDAQ:RPRX) CFO Sells $2,774,234.34 in Stock - MarketBeat
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells $931,686.69 in Stock - MarketBeat
Is Royalty Pharma plc stock a good choice for value investors2025 Market Sentiment & Verified Technical Trade Signals - Newser
Denali Therapeutics stock rises on $275 million royalty deal with Royalty Pharma - Investing.com Australia
Denali, Royalty Pharma Ink $275Mln Royalty Financing Agreement - Nasdaq
Denali Therapeutics and Royalty Pharma ink $275 million funding deal By Investing.com - Investing.com Nigeria
Royalty Pharma, Denali Sign $275 Million Hunter Syndrome Treatment Royalty Deal - marketscreener.com
Denali Therapeutics and Royalty Pharma ink $275 million funding deal - Investing.com
Denali Therapeutics enters $275 million royalty funding agreement with Royalty Pharma - Investing.com
How Royalty Pharma plc (RPD) stock correlates with oil marketsMarket Activity Summary & Capital Efficiency Focused Strategies - Newser
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Agreement for Tividenofusp Alfa Development - Quiver Quantitative
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement - The Manila Times
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement - The Manila Times
Denali Therapeutics (Nasdaq: DNLI) lands $275M, 9.25% tividenofusp alfa royalty deal - Stock Titan
OMERS ADMINISTRATION Corp Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Is Royalty Pharma plc (RPD) stock attractive post correction2025 Trading Volume Trends & Real-Time Market Sentiment Alerts - Newser
How Royalty Pharma plc (RPD) stock trades pre earningsQuarterly Profit Summary & Weekly High Return Forecasts - Newser
How Royalty Pharma plc (RPD) stock performs in easing cyclesJuly 2025 Action & Community Consensus Stock Picks - Newser
Arrowstreet Capital Limited Partnership Purchases 1,615,706 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma EVP Coyne sells shares worth $2.77 million By Investing.com - Investing.com Nigeria
Urist Marshall sells Royalty Pharma (RPRX) shares worth $1.66 million By Investing.com - Investing.com Nigeria
Royalty Pharma EVP Coyne sells shares worth $2.77 million - Investing.com
1.63%
1.90%
자본화:
|
볼륨(24시간):